» Articles » PMID: 21764670

Clinical Performance of Drug-eluting Stents with Biodegradable Polymeric Coating: a Meta-analysis and Systematic Review

Overview
Date 2011 Jul 19
PMID 21764670
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Different biodegradable-polymer drug-eluting stents have not yet been systematically analysed. We sought to; 1) evaluate the risk of target lesion revascularisation (TLR) and definite stent thrombosis (DST) among different groups of biodegradable-polymer (BioPol) DES, and 2) to compare them with permanent polymer (PermPol) DES.

Methods And Results: We searched PubMed and relevant sources from January 2005 until October 2010. Inclusion criteria were (a) Implantation of a drug-eluting stent with biodegradable polymer; (b) available follow-up data for at least one of the clinical end-points (TLR/DST) at short term (30 days) and/or mid-term (one year). A total of 22 studies, including randomised and observational studies, with 8264 patients met the selection criteria; nine studies (2042 patients) in whom biodegradable-polymer sirolimus eluting stents (BioPol-SES) were implanted, eight studies (1731 patients) in whom biodegradable-polymer paclitaxel eluting stents (BioPol-PES) were implanted, and seven studies (4491 patients) in whom biodegradable-polymer biolimus-A9 eluting stents (BioPol-BES) were implanted. At 30 days, there was a higher risk of DST (p=0.04) and subsequently TLR (p=0.006) in the BioPol-BES compared to BioPol-SES, with no significant difference in the other stent comparisons. At 1-year, there was higher risk of TLR in the BioPol-PES (p=0.01), and the BioPol-SES (p=0.04) compared to BioPol-BES. One-year stent thrombosis was not statistically different between the studied groups (overall p=0.2). In another analysis comprising seven randomised trials comparing BioPol-DES (3778 patients) and PermPol-DES (3291 patients), the risks of TLR and stent thrombosis at 1-year were not significantly different (p=0.5 for both).

Conclusions: Performance of different BioPol-DES seems to vary from each other. The short- and mid-term success rates may not be superimposable. Furthermore, they may not be necessarily better than PermPol-DES.

Citing Articles

The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy.

Hussain Y, Saito S, Curtis M, Kereiakes D, Baumbach A, Zidar J J Soc Cardiovasc Angiogr Interv. 2024; 2(3):100629.

PMID: 39130696 PMC: 11307614. DOI: 10.1016/j.jscai.2023.100629.


Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes.

Zhang H, Wang X, Deng W, Wang S, Ge J, Toft E Medicine (Baltimore). 2016; 95(38):e4820.

PMID: 27661023 PMC: 5044893. DOI: 10.1097/MD.0000000000004820.


Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.

Parsa E, Saroukhani S, Majlessi F, Poorhosseini H, Lofti-Tokaldany M, Jalali A Tex Heart Inst J. 2016; 43(2):126-30.

PMID: 27127426 PMC: 4845570. DOI: 10.14503/THIJ-14-4997.


Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model.

Lim K, Park J, Jeong M, Bae I, Nah J, Park D J Mater Sci Mater Med. 2016; 27(4):66.

PMID: 26886814 DOI: 10.1007/s10856-015-5622-0.


Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up.

Wang Q, Zhou Y, Qiao T, Zhou M Exp Ther Med. 2015; 9(4):1545-1556.

PMID: 25780467 PMC: 4353767. DOI: 10.3892/etm.2015.2293.